MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors - sprookjes - yvandenbroek - TriplyDB

MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors

MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors

http://www.wikidata.org/entity/Q27350187

about

Single and Multiple Gene Manipulations in Mouse Models of Human Cancer DNA damage response and prostate cancer: defects, regulation and therapeutic implications Multiligand specificity and wide tissue expression of GPRC6A reveals new endocrine networks MYC activation is a hallmark of cancer initiation and maintenance Genetically engineered mouse models of prostate cancer Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers.Id4 deficiency attenuates prostate development and promotes PIN-like lesions by regulating androgen receptor activity and expression of NKX3.1 and PTEN Novel bone endocrine networks integrating mineral and energy metabolism HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network.Inactivation of MYC reverses tumorigenesis.Mouse models of prostate cancer: picking the best model for the question.Molecular classification of prostate cancer using curated expression signatures Transcriptional Repressor DAXX Promotes Prostate Cancer Tumorigenicity via Suppression of Autophagy.Prostate cancer - a biomarker perspective.JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate.Development of animal models underlining mechanistic connections between prostate inflammation and cancer Hunk negatively regulates c-myc to promote Akt-mediated cell survival and mammary tumorigenesis induced by loss of Pten.Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee.Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer Advancing precision medicine for prostate cancer through genomics.Metformin targets c-MYC oncogene to prevent prostate cancer.Therapeutic Approaches Targeting MYC-Driven Prostate Cancer Revisiting the nucleolus: from marker to dynamic integrator of cancer signaling.Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer.AKT1, LKB1, and YAP1 Revealed as MYC Interactors with NanoLuc-Based Protein-Fragment Complementation Assay.Drug discovery in advanced prostate cancer: translating biology into therapy.Next-generation sequencing reveals novel rare fusion events with functional implication in prostate cancer.ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss.Effect of Metformin, Rapamycin, and Their Combination on Growth and Progression of Prostate Tumors in HiMyc Mice.HMGB1: A Promising Therapeutic Target for Prostate Cancer.Myc-dependent purine biosynthesis affects nucleolar stress and therapy response in prostate cancer.RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis.Is the bench getting closer to the bedside in the war on cancer? A quick look at prostate cancer.Incidence of Mucinous Metaplasia in the Prostate of FVB/N Mice (Mus musculus).AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer.The Genomics of Prostate Cancer: emerging understanding with technologic advances.

P2860

Q26783920-8E6E7C73-C3C3-49B7-B5E9-BFA5396C1F24 Q26829155-D689CEBD-3DED-4607-A158-0017AFE9F972 Q26862997-E2BE0B9C-72C4-419D-BA3C-972B26C54E74 Q27026026-8B0DCEA4-C841-4A1B-B9CF-0A849CE28A17 Q27026768-B3D49B15-0428-4E3A-A823-8714762AB96D Q27309997-555E56AD-442F-4B42-8376-8D32137F6FD6 Q28592943-72AB33DE-1A19-40F1-B52E-782E1D9E67AC Q33572134-B3A58433-5EEA-43E0-80BD-44B599FCB8FE Q33623369-1B154A98-1F4E-4012-81A9-819F9F4AB0B6 Q33784668-098DE580-023A-495C-A1EB-F92C098465E4 Q33940867-370BC802-4139-4056-883B-449E1B4A768E Q35641563-1B6352F3-4FAC-4128-AA29-46B8CACEE704 Q35860607-155487E9-CBA8-4652-8CBC-F00331CB7793 Q35992814-D921B74F-A8F2-40DC-9ED8-400F28006BE9 Q36132632-6FB9F0D0-4020-4EF3-9413-97FA9B3E08F3 Q36718905-BEE0EC4A-ACC0-4157-A599-DD69C0470A7A Q36762496-3C353465-5D91-414F-8FEA-14A668EFFAA8 Q36815316-8150289E-4112-4645-AC16-55D0B83DD1F6 Q37221588-FE1D1085-D309-48F5-94C7-DC9D164E8BA1 Q37255151-8D1E1DE2-70EF-4E47-858A-8B1BADDA00D4 Q37354564-A776E278-9681-451B-95FD-96D22309C5B4 Q37676253-3596BCE8-854C-462A-985C-3C0C4CBB4541 Q38042589-493A529E-1698-4CA1-9B36-23EF7D33D3F9 Q38112122-8F17EC52-6B00-45B4-B030-41FCD2647E39 Q38721347-FC40DDAF-5698-4FCA-85D6-F36364BAB34A Q38839110-6038818A-2229-4F5A-8680-F11109F7BAB0 Q39027992-F2414CE4-4D45-444E-9FE4-C6A50535665F Q39132148-30806325-965B-4F7D-9B75-7C3E527537F9 Q41020029-6D6459A5-2ED7-44C3-B273-1ECFC8BD21F5 Q41136849-CFB52971-83C6-40D6-960B-0C35FB0E4705 Q41261272-69086B98-EDFE-4C21-9522-B3FDE041F081 Q41960947-0223F574-0B2B-4CE3-AB27-FA5C91193E89 Q42175046-45FBE31F-A574-4770-A6A5-278E751E10C0 Q42359860-EFF4653E-6FE7-491F-A1AA-ACB129BC70B1 Q42551982-A8FF9964-F1FD-4FEF-AEF5-73611C53BF6B Q48317607-EC76C939-7E81-4724-9E0B-F2EF726B0D1E

P2860

MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors

http://www.wikidata.org/entity/Q27350187

description

2011 nî lūn-bûn

@nan

2011 թուականին հրատարակուած գիտական յօդուած

@hyw

2011 թվականին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

MYC cooperates with AKT in pro ...... sensitivity to mTOR inhibitors

@ast

MYC cooperates with AKT in pro ...... sensitivity to mTOR inhibitors

@en

MYC cooperates with AKT in pro ...... sensitivity to mTOR inhibitors

@nl

type

label

MYC cooperates with AKT in pro ...... sensitivity to mTOR inhibitors

@ast

MYC cooperates with AKT in pro ...... sensitivity to mTOR inhibitors

@en

MYC cooperates with AKT in pro ...... sensitivity to mTOR inhibitors

@nl

prefLabel

MYC cooperates with AKT in pro ...... sensitivity to mTOR inhibitors

@ast

MYC cooperates with AKT in pro ...... sensitivity to mTOR inhibitors

@en

MYC cooperates with AKT in pro ...... sensitivity to mTOR inhibitors

@nl

P1433

Q27350187-ABDB44E0-311D-4450-AAE7-D17F910AE5C3

P1476

Q27350187-36FE8E64-6BFB-4093-8950-35E23C8EFF84

P2093

Q27350187-3CD09076-2258-4B5C-8AB8-97F9D2A57AD7

Q27350187-7BBD310A-2925-4511-8CDF-D7B74A5EC381

Q27350187-7E26BE60-88D8-4D9C-B297-C0D168664A83

Q27350187-A2DDC102-D110-4856-9CE5-857109675671

Q27350187-BC2BE17B-3F9C-4D33-B35E-93B23365640E

Q27350187-C7025ED8-FAD4-489B-A8C3-3174DE9946C4

Q27350187-CAA7A3C2-6390-47CB-A316-E33F250EC59F

Q27350187-E930C7CD-A2C9-4777-8442-17051DB3F8CA

Q27350187-EF9948BE-43CC-4FE5-B03C-32AF717C69E2

P2860

Q27350187-0B32198A-7C09-4220-8CE9-4190B818178D

Q27350187-0D056A56-3CA2-45F5-AA4E-590C7B921749

Q27350187-11FFFAE4-8449-4C52-B533-EA9CD82D40E4

Q27350187-12FF48C3-3362-4DF8-AAB4-0E6556851821

Q27350187-18BCC1B1-D6B2-4C1F-861A-79BA1C0D21AB

Q27350187-18C8CB2B-CAAA-4EBE-8996-F098CBEC70D6

Q27350187-2BC665AA-5502-47D9-9E06-E92D07D2B233

Q27350187-3B0F8CCB-1B9D-4072-B569-977312DCDE87

Q27350187-4231C369-0868-4AFF-86D2-9638AE934DCF

Q27350187-4493906C-F8A0-40B8-9AEC-E197DB018066

P304

Q27350187-762F2F79-9419-4DBB-8679-F1D8ABFA050E

P31

Q27350187-6AAF21E8-D9A9-4C49-A02D-0543400D7940

P356

Q27350187-D5C77AEE-7FBE-42E0-8A9F-A590E4D93BFB

P407

Q27350187-8C03CBEA-D4F0-4A13-A4B7-434887715657

P433

Q27350187-A30ACFAF-7543-4399-9E51-28A4B385F796

P478

Q27350187-E3771554-F8F8-4664-B218-259B4DC68413

P50

Q27350187-3CD53AD1-57CB-4CD9-871C-7C2D0D56B598

P577

Q27350187-C27119EE-87FE-4B0F-ABC8-F5B0870B6C01

P5875

Q27350187-1873207B-7685-4352-9233-0ED30CB731EA

P698

Q27350187-D62D78BF-41A5-4814-BEB8-07FC107DD6D4

P932

Q27350187-8B6167A4-6461-4D83-A084-2E96617FA354

P356

JOURNAL.PONE.0017449

P1433

P1476

MYC cooperates with AKT in pro ...... sensitivity to mTOR inhibitors

@en

P2093

Barry S Taylor

http://www.w3.org/2001/XMLSchema#string

Brett S Carver

http://www.w3.org/2001/XMLSchema#string

Charles L Sawyers

http://www.w3.org/2001/XMLSchema#string

Haley Hieronymus

http://www.w3.org/2001/XMLSchema#string

John Wongvipat

http://www.w3.org/2001/XMLSchema#string

Katharine Ellwood-Yen

http://www.w3.org/2001/XMLSchema#string

Nicola J Clegg

http://www.w3.org/2001/XMLSchema#string

Suzana S Couto

http://www.w3.org/2001/XMLSchema#string

William L Gerald

http://www.w3.org/2001/XMLSchema#string

P2860

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis

Pten dose dictates cancer progression in the prostate

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

Molecular mechanisms of mTOR-mediated translational control

mTOR and cancer: insights into a complex relationship

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

Integrative genomic profiling of human prostate cancer

P304

e17449

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0017449

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50364542

http://www.w3.org/2001/XMLSchema#string

P698

21394210

http://www.w3.org/2001/XMLSchema#string

P932

3048873

http://www.w3.org/2001/XMLSchema#string